Skip to main content
1-featuredimage

Welcome to hubXchange's CNS Therapeutics Xchange San Francisco 2026.

This event brings together senior-level scientists and executives from the pharmaceutical and biotech sectors to tackle key challenges in Target Discovery, Biomarkers, Blood Brain Barrier,  Preclinical Models and Clinical Development

Attendees can engage in roundtable discussions, pre-booked 1:1 meetingspresentations, and networking sessions with top industry experts, to foster collaboration and find innovative solutions to accelerate CNS Therapeutics.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking.

San Francisco | Thursday 10th September 2026 | 08:00am - 05:45pm

VIEW AGENDA    REGISTER FOR FREE    OUR PARTNERS    EVENT INFORMATION

Why choose hubXchange?

 

FULL AGENDA

Click the topic titles to find out more!

Loading
08:00
  1. Registration
    30 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
08:30
  1. 30 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
09:05
  1. Target Discovery
    60 mins
    • Target Discovery
    What is the relationship between human dose, target occupancy, and duration of target engagement? How does target engagement translate into modulation of disease-relevant biomarkers? How does disease ...
  2. Biomarkers
    60 mins
    • Biomarkers
  3. Blood Brain Barrier
    60 mins
    • Blood Brain Barrier
    What are the principal receptors and transporters currently being targeted for the delivery of proteins and AAV vectors across the BBB? What is known about how the various receptors and transporters t ...
  4. Preclinical Models
    60 mins
    • Preclinical Models
    What are the current unmet needs for disease models? What is the demand from drug discovery teams for in vitro models? What are the current trends in building and adopting in vitro or in vivo disease ...
  5. Clinical Development
    60 mins
    • Clinical Development
    How can using established, regulator-accepted endpoints help derisk development and clarify the regulatory pathway? What lessons can be learned from programmes that failed after using novel or creativ ...
10:10
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
10:40
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
11:10
  1. Morning Refreshments
    10 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
12:20
  1. Networking Lunch
    60 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
13:25
  1. Spotlight Presentation: Organ-on-a-Chip Technology for CNS Discovery: Isogenic iPSC Models of the Human Neurovascular Unit
    30 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
    Organ-on-a-Chip technology is enabling more human-relevant approaches to neuroscience research by recreating key aspects of organ-level physiology in vitro, including tissue-tissue interaction, vascul ...
14:00
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
14:30
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
15:05
  1. Biomarkers
    30 mins
    • Biomarkers
    The Brain–Nose Interface represents a uniquely exposed and anatomically privileged connection between the central nervous system and the nasal cavity. Along olfactory nerves and perivascular pathways ...

    noselab

  2. Target Discovery
    30 mins
    • Target Discovery
  3. Blood Brain Barrier
    30 mins
    • Blood Brain Barrier
  4. Preclinical Models
    30 mins
    • Preclinical Models

    Sygnature Discovery

  5. Clinical Development
    30 mins
    • Clinical Development
    The incorporation of deuterium into drug candidates has evolved from a specialized isotope-labeling technique into a strategic medicinal chemistry approach used to address key development challenges, ...

    Adesis

15:35
  1. Afternoon Refreshments
    10 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development
15:45
  1. Target Discovery
    60 mins
    • Target Discovery
    Omics keeps handing us long lists of candidate targets, but which ones actually matter? How do you distinguish a true driver from a bystander? What does it take to prove that a target matters in the b ...
  2. Blood Brain Barrier
    60 mins
    • Blood Brain Barrier
  3. Preclinical Models
    60 mins
    • Preclinical Models
    What are the main reasons preclinical CNS models often fail to predict human clinical outcomes? How can we improve the biological relevance of animal and in vitro CNS models to better reflect human di ...
  4. Clinical Development
    60 mins
    • Clinical Development
16:45
  1. Evening Drinks Reception
    60 mins
    • Target Discovery
    • Biomarkers
    • Blood Brain Barrier
    • Preclinical Models
    • Clinical Development

EVENT INFORMATION

3-featuredimage

DATES

San Francisco
Sept 10, 2026

Thursday 10th September 2026

 

DoubleTree by Hilton San Francisco Airport Hotel Photo

 

VENUE

 

DoubleTree by Hilton San Francisco Airport Hotel

DoubleTree by Hilton
San Francisco Airport Hotel
835 Airport Blvd, Burlingame
California, 94010-9949

MAP

EVENT PARTNERS

4-featuredimage

EVENT PARTNERS

REGISTRATION FORM - Register for free!

6-featuredimage

Complimentary Registration is only available for Senior Scientists & above, in Pharma & Bio Tech, with an active drug pipeline.
 

For Service Providers, please click here.